EMA (EU)
GUIDANCE FINAL
Semaglutide and FlexTouch solution for injection in pre-filled pen product-specific bioequivalence guidance - various strengths
Published: 7/14/2026Detected: 7/14/2026
Summary preview
Product-specific bioequivalence (BE) guidance for semaglutide pre-filled pen products specifies how to demonstrate PK equivalence across multiple strengths and whether a PK BE study can be reduced or waived.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountOfficial Source Document Source Verified
Access the original document directly from EMA.
More from EMA (EU)
- Pharmacovigilance Risk Assessment Committee (PRAC): 23 - 26 November 202611/23/2026
- Seventeenth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines11/20/2026
- EMA annual call with General Practitioner Organisations' representatives11/20/2026
- Digitalisation and artificial intelligence in pharmaceutical manufacturing: Quality Innovation Group (QIG) - Follow-up roundtable meeting11/18/2026
- Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - November 202611/18/2026